Skip to content

Reproducibility Study of Overactive Bladder Symptom Score [OABSS]

Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 1: Reproducibility -

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01122550
Acronym
RESORT-1
Enrollment
50
Registered
2010-05-13
Start date
2009-09-30
Completion date
2010-08-31
Last updated
2010-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Keywords

OABSS, IPSS, PPBC, 3-day micturition diary

Brief summary

The purpose of this study is to evaluate its reproducibility of overactive bladder symptom score (OABSS) and to evaluate its correlation to other measures of OAB symptoms.

Interventions

None listed

Sponsors

Astellas Pharma Indonesia Inc.
CollaboratorINDUSTRY
Astellas Pharma Inc
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Symptoms OAB for 3 months or longer * At least 1 urgency episode in last 3 days * Symptoms of OAB as verified by 3-day micturition diary prior to Visit 1, defined by: * Number of micturition per day ≥8 * Number of urgency episodes in 3 days ≥1

Exclusion criteria

* Significant stress incontinence or mixed stress/urge incontinence * Subjects with indwelling catheters or practicing intermittent self-catheterization * Symptomatic urinary tract infection, chronic inflammation * Diabetic neuropathy * Drug or non-drug treatment for OAB was started, quitted or changed in 4 weeks * Participation in any clinical trial in 30 days

Design outcomes

Primary

MeasureTime frame
OABSSWeeks 0 and 2

Secondary

MeasureTime frame
International Prostate Symptom Score (IPSS)Weeks 0 and 2
Quality of Life (QOL) scoreWeeks 0 and 2
Patient Perception of Bladder Condition (PPBC)Weeks 0 and 2

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026